综述:饮酒对代谢功能障碍相关脂肪性肝病发生与进展的影响
该叙述性综述检索截至2025年6月30日的流行病学与机制研究,评估饮酒对MASLD进展的多方面影响。结果显示,即使中等量饮酒也可通过氧化应激、脂质代谢紊乱和肠道菌群失调等机制加重肝脂肪变,并加速向脂肪性肝炎、纤维化和肝硬化进展;流行病学研究显示饮酒量与肝病严重程度呈剂量依赖性关系,在肥胖或代谢综合征患者中协同效应尤为明显。
要点
- 即使中等量饮酒也可通过多重机制加重MASLD患者的肝脂肪变。
- 饮酒量与肝病严重程度呈剂量依赖性,肥胖或代谢综合征者协同效应更明显。
- 标准化评估饮酒情况对MASLD风险分层和个体化治疗至关重要。
核心结论
- 饮酒通过协同机制放大MASLD的进展,标准化评估饮酒对风险分层和个体化治疗策略至关重要。
研究设计与样本
- 叙述性综述,检索截至2025年6月30日的流行病学与机制研究,主题为饮酒与MASLD代谢功能障碍的交互作用。
主要发现
- 即使中等量饮酒也可通过氧化应激、脂质代谢紊乱和肠道菌群失调等多个相互关联的机制加重肝脂肪变。
- 上述改变触发炎症级联反应,加速代谢功能障碍个体从单纯脂肪变向脂肪性肝炎、纤维化和肝硬化进展。
- 流行病学研究显示饮酒量与肝病严重程度呈剂量依赖性关系,在肥胖或代谢综合征患者中协同效应尤为明显。
临床怎么用
- 临床应标准化评估MASLD患者的饮酒情况,用于风险分层并据此制定个体化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is recognised as a globally prevalent chronic liver disease, primarily driven by metabolic risk factors such as insulin resistance, obesity, dyslipidaemia and impaired glucose metabolism. Traditionally considered distinct from alcohol-related liver disease, MASLD is increasingly being re-evaluated in light of new evidence regarding the role of alcohol consumption. AIMS: To clarify the multifaceted effects of alcohol intake on the progression of MASLD. We focus on the underlying pathophysiological mechanisms, clinical implications and the challenges associated with risk stratification in affected individuals. METHODS: We conducted a narrative review of epidemiological and mechanistic studies on the interaction between alcohol intake and metabolic dysfunction in MASLD up to 30 June 2025. RESULTS: Accumulating evidence indicates that even moderate alcohol consumption can amplify hepatic steatosis through multiple interconnected mechanisms, including oxidative stress, disrupted lipid metabolism and gut microbiota dysbiosis. These changes trigger inflammatory cascades and accelerate the progression from simple steatosis to steatohepatitis, fibrosis and cirrhosis in individuals with underlying metabolic dysfunction. Epidemiological studies have revealed a dose-dependent relationship between alcohol intake and liver disease severity, with synergistic effects particularly evident in patients with obesity or metabolic syndrome. CONCLUSIONS: Alcohol amplifies MASLD progression through synergistic mechanisms. Standardised evaluation of alcohol use is critical for risk stratification and the development of personalised treatment strategies.
引用
- Lei Y, Zhu Y, Ni W, et al. Review Article: Impact of Alcohol Consumption on the Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. Aliment Pharmacol Ther. 2025. PMID: 40833280. doi:10.1111/apt.70335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。